000277980 001__ 277980
000277980 005__ 20250430100241.0
000277980 0247_ $$2doi$$a10.1016/j.neuroscience.2025.03.050
000277980 0247_ $$2pmid$$apmid:40185387
000277980 0247_ $$2ISSN$$a0306-4522
000277980 0247_ $$2ISSN$$a1873-7544
000277980 037__ $$aDZNE-2025-00512
000277980 041__ $$aEnglish
000277980 082__ $$a610
000277980 1001_ $$aMehreen, Mehwish$$b0
000277980 245__ $$aChenodeoxycholic Acid-Mediated neuroprotection via α-synuclein and BDNF Modulation in MPTP-Induced mouse model of Parkinson's disease.
000277980 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000277980 3367_ $$2DRIVER$$aarticle
000277980 3367_ $$2DataCite$$aOutput Types/Journal article
000277980 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745917087_9396
000277980 3367_ $$2BibTeX$$aARTICLE
000277980 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277980 3367_ $$00$$2EndNote$$aJournal Article
000277980 520__ $$aParkinson's disease (PD) remains a major challenge in the field of neurodegenerative diseases and requires innovative therapeutic approaches. In this study, we investigated the therapeutic potential of chenodeoxycholic acid (CDCA) in PD using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model. CDCA, a naturally occurring bile acid, has previously shown promise in various neurological disorders by reducing neuronal degeneration and promoting neuronal health, however its utility in PD has not been studied. We divided mice into a control group, an MPTP-induced PD model and a treatment group injected with CDCA. CDCA reduced motor impairment and ameliorated anxiety-like behavior as assessed through the pole and open field test, demonstrated antidepressant effects in the forced swim and tail suspension test, and results of the Y-maze test showed improved cognitive performance. Furthermore, the effective defense against MPTP-induced dopaminergic degeneration was provided by CDCA by improving the morphological and histological features of neurons in the midbrain, hippocampus, cortex and cerebellum. Analysis via RT-PCR revealed that CDCA significantly mitigated MPP + -induced elevations in α-synuclein levels, indicating its potential to preserve neuronal function by modulating synaptic integrity. Additionally, CDCA effectively reduced the associated toxicity by enhancing the low levels of brain-derived neurotrophic factor. Conclusively, given the increasing prevalence of PD and the urgent need for effective neuroprotective strategies, our findings suggest that CDCA exerts neuroprotective effects in an MPTP-induced PD model. These results highlight CDCA as a promising candidate for further investigation in PD therapy and provide a basis for further research into bile acid-based treatments in neurodegenerative diseases.
000277980 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000277980 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000277980 650_7 $$2Other$$aBDNF
000277980 650_7 $$2Other$$aChenodeoxycholic acid
000277980 650_7 $$2Other$$aMPTP
000277980 650_7 $$2Other$$aParkinson’s disease
000277980 650_7 $$2Other$$aα-synuclein
000277980 7001_ $$aAli, Mehak$$b1
000277980 7001_ $$aTariq, Huraira$$b2
000277980 7001_ $$aNoor, Aneeqa$$b3
000277980 7001_ $$aMumtaz, Sara$$b4
000277980 7001_ $$0P:(DE-2719)9000358$$aZafar, Saima$$b5$$eLast author$$udzne
000277980 773__ $$0PERI:(DE-600)1498423-4$$a10.1016/j.neuroscience.2025.03.050$$gVol. 573, p. 442 - 450$$p442 - 450$$tNeuroscience$$v573$$x0306-4522$$y2025
000277980 8564_ $$uhttps://pub.dzne.de/record/277980/files/DZNE-2025-00512%20SUP.zip
000277980 8564_ $$uhttps://pub.dzne.de/record/277980/files/DZNE-2025-00512.pdf
000277980 8564_ $$uhttps://pub.dzne.de/record/277980/files/DZNE-2025-00512.pdf?subformat=pdfa$$xpdfa
000277980 909CO $$ooai:pub.dzne.de:277980$$pVDB
000277980 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000277980 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000277980 9141_ $$y2025
000277980 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-19$$wger
000277980 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROSCIENCE : 2022$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-19
000277980 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-19
000277980 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000277980 980__ $$ajournal
000277980 980__ $$aVDB
000277980 980__ $$aI:(DE-2719)1440011-1
000277980 980__ $$aUNRESTRICTED